BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 28629427)

  • 1. Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases.
    García-Caballero M; Paupert J; Blacher S; Van de Velde M; Quesada AR; Medina MA; Noël A
    J Hematol Oncol; 2017 Jun; 10(1):122. PubMed ID: 28629427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
    Kodera Y; Katanasaka Y; Kitamura Y; Tsuda H; Nishio K; Tamura T; Koizumi F
    Breast Cancer Res; 2011 Jun; 13(3):R66. PubMed ID: 21693010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling.
    Qin T; Liu Z; Wang J; Xia J; Liu S; Jia Y; Liu H; Li K
    Cancer Biol Med; 2020 Aug; 17(3):753-767. PubMed ID: 32944404
    [No Abstract]   [Full Text] [Related]  

  • 4. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.
    Chen HM; Tsai CH; Hung WC
    Oncotarget; 2015 Jun; 6(17):14940-52. PubMed ID: 25909285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 "multi-points priming" mechanisms in vitro and in vivo.
    Li XP; Jing W; Sun JJ; Liu ZY; Zhang JT; Sun W; Zhu W; Fan YZ
    BMC Cancer; 2015 Jul; 15():527. PubMed ID: 26187792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.
    Roberts N; Kloos B; Cassella M; Podgrabinska S; Persaud K; Wu Y; Pytowski B; Skobe M
    Cancer Res; 2006 Mar; 66(5):2650-7. PubMed ID: 16510584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A heparin conjugate, LHbisD4, inhibits lymphangiogenesis and attenuates lymph node metastasis by blocking VEGF-C signaling pathway.
    Choi JU; Chung SW; Al-Hilal TA; Alam F; Park J; Mahmud F; Jeong JH; Kim SY; Byun Y
    Biomaterials; 2017 Sep; 139():56-66. PubMed ID: 28586719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase.
    Matsui J; Funahashi Y; Uenaka T; Watanabe T; Tsuruoka A; Asada M
    Clin Cancer Res; 2008 Sep; 14(17):5459-65. PubMed ID: 18765537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and VEGF-D/VEGFR-3 with norcantharidin.
    Liu ZY; Qiu HO; Yuan XJ; Ni YY; Sun JJ; Jing W; Fan YZ
    Int J Oncol; 2012 Nov; 41(5):1762-72. PubMed ID: 22922710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel application assigned to toluquinol: inhibition of lymphangiogenesis by interfering with VEGF-C/VEGFR-3 signalling pathway.
    García-Caballero M; Blacher S; Paupert J; Quesada AR; Medina MA; Noël A
    Br J Pharmacol; 2016 Jun; 173(12):1966-87. PubMed ID: 27018653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model.
    Wen J; Fu AF; Chen LJ; Xie XJ; Yang GL; Chen XC; Wang YS; Li J; Chen P; Tang MH; Shao XM; Lu Y; Zhao X; Wei YQ
    Int J Cancer; 2009 Jun; 124(11):2709-18. PubMed ID: 19219913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phomaketide A Inhibits Lymphangiogenesis in Human Lymphatic Endothelial Cells.
    Tai HC; Lee TH; Tang CH; Chen LP; Chen WC; Lee MS; Chen PC; Lin CY; Chi CW; Chen YJ; Lai CT; Chen SS; Liao KW; Lee CH; Wang SW
    Mar Drugs; 2019 Apr; 17(4):. PubMed ID: 30959907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.
    He Y; Kozaki K; Karpanen T; Koshikawa K; Yla-Herttuala S; Takahashi T; Alitalo K
    J Natl Cancer Inst; 2002 Jun; 94(11):819-25. PubMed ID: 12048269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular control of lymphatic metastasis.
    Achen MG; Stacker SA
    Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.
    Whitehurst B; Flister MJ; Bagaitkar J; Volk L; Bivens CM; Pickett B; Castro-Rivera E; Brekken RA; Gerard RD; Ran S
    Int J Cancer; 2007 Nov; 121(10):2181-91. PubMed ID: 17597103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45A.
    Lee E; Koskimaki JE; Pandey NB; Popel AS
    Neoplasia; 2013 Feb; 15(2):112-24. PubMed ID: 23441126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion.
    Tacconi C; Correale C; Gandelli A; Spinelli A; Dejana E; D'Alessio S; Danese S
    Gastroenterology; 2015 Jun; 148(7):1438-51.e8. PubMed ID: 25754161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of lymphangiogenesis by soluble vascular endothelial growth factor receptor-2 in a mouse lung cancer model.
    Maehana S; Nakamura M; Ogawa F; Imai R; Murakami R; Kojima F; Majima M; Kitasato H
    Biomed Pharmacother; 2016 Dec; 84():660-665. PubMed ID: 27697638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3-O-Acetyloleanolic acid inhibits VEGF-A-induced lymphangiogenesis and lymph node metastasis in an oral cancer sentinel lymph node animal model.
    Hwang-Bo J; Bae MG; Park JH; Chung IS
    BMC Cancer; 2018 Jul; 18(1):714. PubMed ID: 29976150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.